meRfi®-GM
Diffuse Large B-Cell Lymphoma (DLBCL)
Welcome to meRfi-GM!
meRfi-GM provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
Navigation
Contents
Diffuse Large B-cell Lymphoma (DLBCL) is the most common subtype of Non-Hodgkin Lymphoma, with the majority of patients (pts) achieving long-term survival due to the curative nature of frontline therapy.
Diffuse large B-cell lymphoma comprises a heterogenous group of morphologically, genetically, and clinically distinct diseases.
Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive lymphoma.
Relapsed or refractory diffuse large B-cell lymphoma (DLBCL) has a poor prognosis.
Epidemiological studies have established that HCV is associated with [Large Cell Lymp…
References (Sources)
- DLBCL’s New Genomics: The Bridge and the Chasm
- Emerging synthetic drugs for the treatment of diffuse large B-cell lymphoma
- Evaluating efficacy and safety of loncastuximab tesirine injection for the treatment of adult patients with relapsed or refractory large B-cell lymphoma
- Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
- Global burden of cancers attributable to infections in 2008: a review and synthetic analysisReview
- Impaired Immune Health in Survivors of Diffuse Large B-Cell Lymphoma
- Toward a New Molecular Taxonomy of Diffuse Large B-cell LymphomaReview